As of November 10, 2026, Karyopharm Therapeutics Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on May 28, 2026 (Form 8-K, May 28, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Karyopharm Therapeutics Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Karyopharm Therapeutics Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-05-28. Every row below is cited to the filing it comes from, and this page adds each new change as Karyopharm Therapeutics Inc. files it.
Also on the record for Karyopharm Therapeutics Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| November 9, 2026 | Stake report, Schedule 13G/A, by THE GOLDMAN SACHS GROUP, INC. | 0.9% of the class | 5%+ stakes | Source |
| October 28, 2026 | Stake report, Schedule 13G/A, by Integrated Core Strategies (US) LLC | 0.2% of the class | 5%+ stakes | Source |
| October 8, 2026 | Stake report, Schedule 13G/A, by Anders Hove | 4.5% of the class | 5%+ stakes | Source |
| September 25, 2026 | Stake report, Schedule 13G/A, by Anders Hove | 5.7% of the class | 5%+ stakes | Source |
| September 25, 2026 | Stake report, Schedule 13G/A, by Anders Hove | 5.7% of the class | 5%+ stakes | Source |
| September 4, 2026 | Stake report, Schedule 13G, by Integrated Core Strategies (US) LLC | 5.7% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Commodore Capital LP | — | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by RA Capital Management, L.P. | 9.9% of the class | 5%+ stakes | Source |
| August 12, 2026 | Stake report, Schedule 13G/A, by Adage Capital Management, L.P. | 6.78% of the class | 5%+ stakes | Source |
| August 11, 2026 | Stake report, Schedule 13G/A, by THE GOLDMAN SACHS GROUP, INC. | 6.3% of the class | 5%+ stakes | Source |
| July 28, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.6% of the class | 5%+ stakes | Source |
| June 5, 2026 | Stake report, Schedule 13G/A, by T. Rowe Price Investment Management, Inc. | 6.6% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Karyopharm Therapeutics Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Karyopharm Therapeutics Inc. and the records around it.
Karyopharm Therapeutics Inc. elsewhere on the record
Companies that share a holder
- J. Wood Capital Advisors LLC also filed stake reports on 1 other company: Cyclerion Therapeutics, Inc. (Oct 2026)
- ACORN BIOVENTURES, L.P. also filed stake reports on 5 other companies: Athira Pharma, Inc. (Aug 2026), enGene Therapeutics Inc. (Jul 2026), OnKure Therapeutics, Inc. (Apr 2026)
- Opaleye Management Inc. also filed stake reports on 12 other companies: Codexis, Inc. (Nov 2026), Gossamer Bio, Inc. (Nov 2026), Pasithea Therapeutics Corp. (Nov 2026)
Watch Karyopharm Therapeutics Inc.
Get an email when Karyopharm Therapeutics Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Karyopharm Therapeutics Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Karyopharm Therapeutics Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Karyopharm Therapeutics Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 33 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-05-28 | Reported | not named in the filing | 8-K, 2026-05-28 |
New leaders reset buying decisions — get the Full Report on Karyopharm Therapeutics Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Karyopharm Therapeutics Inc., with the record behind each one.
Find candidates like senior executive at Karyopharm Therapeutics Inc.Every change, in the filing's words
Reported
The following PSU awards were approved for the following named executive officers and the Chief Financial Officer: (i) Dr. Reshma Rangwala, Executive Vice President, Chief Medical Officer and Head of Research - 150,000 PSUs for each of the First PSU Award and the Second PSU Award; (ii) Lori Macomber, Executive Vice President, Chief Financial Officer and Treasurer - 130,000 PSUs for each of the First PSU Award and the Second PSU Award; and (iii) Stuart Poulton, Executive Vice President, Chief Development Officer - 130,000 PSUs for each of the First PSU Award and the Second PSU Award.
- Amendment to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended At th e 2026 Annual Meeting of Stockholders of Karyopharm Therapeutics Inc. (the "Company") held on May 21, 2026 (the "Annual Meeting"), the Company's stockholders approved an amendment (the "2022 Plan Amendment") to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended (the "2022 Plan" and, as further amended by the 2022 Plan Amendment, the "Amended 2022 Plan").
- The 2022 Plan Amendment, which had previously been adopted by the Company's Board of Directors (the "Board") subject to stockholder approval, increases the number of shares of common stock of the Company available for issuance under the Amended 2022 Plan by 3,000,000 shares.
- Performance-based Equity Awards On May 22, 2026, the Compensation Committee (the "Committee") of the Board approved a broad-based retention program designed to support the continued motivation, retention and incentivization of the Company's employees, including the Company's named executive officers and Chief Financial Officer (the "Retention Program").
- Under the Retention Program, eligible employees will receive two retention equity awards in the form of performance-based restricted stock units ("PSUs") granted under the Amended 2022 Plan, effective as of May 31, 2026.
Tools for this story
Each opens in a new tab, filled in for Karyopharm Therapeutics Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.